Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 24.55%.

  • Dna X's EBITDA Margin fell 87300.0% to 24.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.43%, marking a year-over-year decrease of 318900.0%. This contributed to the annual value of 57.7% for FY2024, which is 582500.0% down from last year.
  • As of Q3 2025, Dna X's EBITDA Margin stood at 24.55%, which was down 87300.0% from 60.16% recorded in Q2 2025.
  • Dna X's 5-year EBITDA Margin high stood at 3.86% for Q1 2025, and its period low was 147.52% during Q4 2024.
  • Over the past 5 years, Dna X's median EBITDA Margin value was 24.55% (recorded in 2025), while the average stood at 36.73%.
  • In the last 5 years, Dna X's EBITDA Margin soared by 693100bps in 2022 and then crashed by -1381700bps in 2024.
  • Over the past 5 years, Dna X's EBITDA Margin (Quarter) stood at 73.71% in 2021, then skyrocketed by 94bps to 4.39% in 2022, then crashed by -113bps to 9.34% in 2023, then plummeted by -1479bps to 147.52% in 2024, then skyrocketed by 83bps to 24.55% in 2025.
  • Its EBITDA Margin was 24.55% in Q3 2025, compared to 60.16% in Q2 2025 and 3.86% in Q1 2025.